ABL1 and cancer: Next our data shows that there is still potential to increase the targeting to highly validated cancer driving genes such as BRAF, ABL1 and EGFR. Our data demonstrate that biochemical potency (illustrated by comparing dabrafenib to vemurafenib) and biochemical selectivity (illustrated by comparing the EGFR inhibitors) are both important for effective targeting of EGFR, BRAF and ABL1 inhibitors to EGFR, BRAF(V600E) and ABL1 transformed cell lines (Figure 5).